Post by Kyinno Biotechnology, Inc.

The emergence of RIPTAC (Regulated Induced Proximity Targeting Chimeras) is expanding the possibilities of induced proximity therapeutics beyond traditional PROTAC technology. Unlike PROTACs, RIPTAC molecules do not rely on protein degradation, creating new opportunities for targeting challenging disease mechanisms while introducing unique requirements for mechanism validation and cell-based screening. To support RIPTAC drug discovery, Kyinno Biotechnology, Inc. has developed a portfolio of Tet-On doxycycline-inducible cell lines that enable tightly controlled target protein expression. These models provide a clean experimental background for evaluating RIPTAC specificity, distinguishing induced proximity from direct binding effects, and supporting mechanism-of-action studies with greater confidence. Whether developing RIPTACs, molecular glues, or other induced proximity therapeutics, Kyinno's inducible cell platforms provide robust tools to accelerate early-stage research and therapeutic development. Learn more about our inducible cell line portfolio or contact us to discuss your project: https://www.kyinno.com/ #RIPTAC #PROTAC #InducedProximity #TargetedTherapies #DrugDiscovery #CancerResearch #CellLineModels #Biotechnology #Kyinno #OncologyResearch